XTX Topco Ltd Has $260,000 Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

XTX Topco Ltd lessened its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 54.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 6,744 shares of the company's stock after selling 8,057 shares during the quarter. XTX Topco Ltd's holdings in Protagonist Therapeutics were worth $260,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the business. Franklin Resources Inc. lifted its holdings in Protagonist Therapeutics by 127.2% in the third quarter. Franklin Resources Inc. now owns 81,591 shares of the company's stock valued at $3,782,000 after buying an additional 45,674 shares during the period. Principal Financial Group Inc. grew its stake in shares of Protagonist Therapeutics by 3,099.4% during the third quarter. Principal Financial Group Inc. now owns 320,832 shares of the company's stock worth $14,437,000 after purchasing an additional 310,804 shares during the period. Arrowstreet Capital Limited Partnership increased its holdings in Protagonist Therapeutics by 36.7% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 216,069 shares of the company's stock valued at $8,340,000 after purchasing an additional 58,002 shares during the last quarter. Assenagon Asset Management S.A. acquired a new position in Protagonist Therapeutics in the fourth quarter valued at about $2,016,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Protagonist Therapeutics by 2.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 578,409 shares of the company's stock worth $22,327,000 after buying an additional 12,906 shares during the last quarter. Institutional investors own 98.63% of the company's stock.

Protagonist Therapeutics Stock Down 1.9 %

PTGX traded down $0.89 during trading hours on Thursday, hitting $44.93. 186,253 shares of the company's stock were exchanged, compared to its average volume of 857,688. The stock has a market cap of $2.76 billion, a price-to-earnings ratio of 16.92 and a beta of 2.30. Protagonist Therapeutics, Inc. has a 1-year low of $24.78 and a 1-year high of $60.60. The stock's 50-day moving average is $45.98 and its two-hundred day moving average is $42.87.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last posted its quarterly earnings data on Friday, February 21st. The company reported $1.98 EPS for the quarter, topping analysts' consensus estimates of ($0.09) by $2.07. The company had revenue of $170.64 million during the quarter, compared to the consensus estimate of $56.65 million. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. On average, equities research analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

Insiders Place Their Bets

In other news, Director William D. Waddill sold 4,000 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $54.25, for a total value of $217,000.00. Following the completion of the sale, the director now directly owns 13,130 shares of the company's stock, valued at $712,302.50. This trade represents a 23.35 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Asif Ali sold 1,756 shares of Protagonist Therapeutics stock in a transaction that occurred on Tuesday, April 22nd. The stock was sold at an average price of $46.00, for a total value of $80,776.00. Following the transaction, the chief financial officer now owns 61,065 shares of the company's stock, valued at $2,808,990. This represents a 2.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 66,532 shares of company stock valued at $3,665,786 in the last 90 days. 5.40% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on PTGX shares. BTIG Research set a $73.00 price target on shares of Protagonist Therapeutics in a research report on Monday, March 3rd. Truist Financial increased their target price on shares of Protagonist Therapeutics from $60.00 to $76.00 and gave the stock a "buy" rating in a report on Tuesday, March 11th. JMP Securities reissued a "market outperform" rating and set a $58.00 price target on shares of Protagonist Therapeutics in a research report on Friday, February 7th. Wedbush reaffirmed an "outperform" rating and set a $70.00 price objective on shares of Protagonist Therapeutics in a research note on Friday, March 28th. Finally, BMO Capital Markets boosted their target price on Protagonist Therapeutics from $62.00 to $72.00 and gave the company an "outperform" rating in a research note on Tuesday, March 11th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $65.44.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.